Krystal Biotech Reports Positive KB113 Clinical Data for Gorlin Syndrome

Key Facts

1Krystal Biotech announced that over 80% of basal cell carcinoma lesions regressed in Gorlin syndrome patients treated with KB113.

2Substantial regression was observed in non-injected lesions, consistent with a systemic immune-mediated abscopal effect.

Krystal Biotech announced that over 80% of basal cell carcinoma lesions regressed in Gorlin syndrome patients treated with its KB113 candidate. According to a company statement released via GlobeNewswire, the initial proof-of-concept data supports the efficacy of the intratumoral immunotherapy in promoting tumor clearance.

The clinical findings highlighted substantial regression in non-injected lesions, consistent with a systemic immune-mediated abscopal effect. Following these developments, KRYS closed at $330.69 on October 14, 2026, having traded between a low of $319.01 and a high of $330.97 during that session.